Evanson Jeff
Insider CIK 1760511 · OTLK Chief Commercial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2024-03-20 | 2024-03-22 | 25,000 | — | $0 | 25,000 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2024-03-07 | 2024-03-11 | 62,484 | $0.42 | $26.2K | 808,459 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2023-04-17 | 2023-04-19 | 192,143 | — | $0 | 192,143 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2023-01-20 | 2023-01-24 | 267,000 | $1.11 | $296.4K | 745,975 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2023-01-19 | 2023-01-19 | 103,255 | $1.22 | $126.0K | 1,012,975 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2023-01-18 | 2023-01-19 | 33,738 | $1.25 | $42.2K | 1,116,230 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2023-01-17 | 2023-01-19 | 27,162 | $1.31 | $35.6K | 1,149,968 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2022-03-31 | 2022-04-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2021-12-21 | 2021-12-23 | 800,000 | — | $0 | 800,000 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2021-12-03 | 2021-12-06 | 35,200 | $1.34 | $47.2K | 1,177,130 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2021-02-23 | 2021-02-25 | 8,554 | $2.09 | $17.9K | 1,141,930 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | S Sale | 2021-02-12 | 2021-02-17 | 56,973 | $2.55 | $145.3K | 1,150,484 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2020-03-19 | 2020-04-21 | 1,207,457 | — | $0 | 1,207,457 | SEC↗ |